Profound Medical
Market Cap
CA$274.4m
Last Updated
2020/06/01 06:09 UTC
Data Sources
Company Financials +
Executive Summary
Profound Medical Corp. operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Profound Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PRN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-0.3%
PRN
0.4%
CA Medical Equipment
1.4%
CA Market
1 Year Return
100.7%
PRN
-14.1%
CA Medical Equipment
-11.3%
CA Market
Return vs Industry: PRN exceeded the Canadian Medical Equipment industry which returned -17.8% over the past year.
Return vs Market: PRN exceeded the Canadian Market which returned -11.4% over the past year.
Shareholder returns
| PRN | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.3% | 0.4% | 1.4% |
| 30 Day | -3.0% | 0.7% | 4.2% |
| 90 Day | -2.3% | -5.3% | -9.4% |
| 1 Year | 100.7%100.7% | -14.1%-14.1% | -8.3%-11.3% |
| 3 Year | 89.6%89.6% | -40.7%-40.7% | 0.04%-9.2% |
| 5 Year | n/a | -28.7%-28.7% | 16.7%-0.01% |
Price Volatility Vs. Market
How volatile is Profound Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Can You Imagine How Profound Medical's (TSE:PRN) Shareholders Feel About The 95% Share Price Increase?1 month ago | Simply Wall St
How Much Are Profound Medical Corp. (TSE:PRN) Insiders Taking Off The Table?2 months ago | Simply Wall St
Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN)Valuation
Is Profound Medical undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRN (CA$17.06) is trading below our estimate of fair value (CA$180.19)
Significantly Below Fair Value: PRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PRN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: PRN is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PRN is overvalued based on its PB Ratio (3.6x) compared to the CA Medical Equipment industry average (3x).
Next Steps
Future Growth
How is Profound Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
65.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: PRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PRN's is expected to become profitable in the next 3 years.
Revenue vs Market: PRN's revenue (54.4% per year) is forecast to grow faster than the Canadian market (5.9% per year).
High Growth Revenue: PRN's revenue (54.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRN's Return on Equity is forecast to be low in 3 years time (7.7%).
Next Steps
Past Performance
How has Profound Medical performed over the past 5 years?
-8.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRN is currently unprofitable.
Growing Profit Margin: PRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PRN is unprofitable, and losses have increased over the past 5 years at a rate of -8.7% per year.
Accelerating Growth: Unable to compare PRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.2%).
Return on Equity
High ROE: PRN has a negative Return on Equity (-27.76%), as it is currently unprofitable.
Next Steps
Financial Health
How is Profound Medical's financial position?
Financial Position Analysis
Short Term Liabilities: PRN's short term assets (CA$73.5M) exceed its short term liabilities (CA$4.5M).
Long Term Liabilities: PRN's short term assets (CA$73.5M) exceed its long term liabilities (CA$3.0M).
Debt to Equity History and Analysis
Debt Level: PRN is debt free.
Reducing Debt: PRN currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Profound Medical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.2yrs
Average board tenure
CEO
Arun Menawat (64yo)
3.83yrs
Tenure
CA$1,974,245
Compensation
Dr. Arun Swarup Menawat, Ph.D., MBA, has been the Chief Executive Officer of Profound Medical Corp. since August 15, 2016. Dr. Menawat served as the Chief Executive Officer and President of Novadaq Technol ...
CEO Compensation Analysis
Compensation vs Market: Arun's total compensation ($USD1.43M) is above average for companies of similar size in the Canadian market ($USD730.29K).
Compensation vs Earnings: Arun's compensation has increased whilst the company is unprofitable.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.83yrs | CA$1.97m | 1.46% CA$4.0m | |
| Independent Director | 2yrs | CA$99.65k | no data | |
| Independent Lead Director | no data | CA$100.90k | no data | |
| Independent Director | 3.42yrs | CA$107.15k | no data | |
| Independent Director | 5yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
4.2yrs
Average Tenure
62yo
Average Age
Experienced Board: PRN's board of directors are considered experienced (4.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.8%.
Top Shareholders
Company Information
Profound Medical Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Profound Medical Corp.
- Ticker: PRN
- Exchange: TSX
- Founded:
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: CA$274.369m
- Shares outstanding: 16.08m
- Website: https://www.profoundmedical.com
Number of Employees
Location
- Profound Medical Corp.
- 2400 Skymark Avenue
- Unit no. 6
- Mississauga
- Ontario
- L4W 5K5
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PRN | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Jun 2015 |
| PROF | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Jun 2015 |
Biography
Profound Medical Corp. operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/01 06:09 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.